Combined treatment with a gastric inhibitory polypeptide receptor antagonist and a peptidyl peptidase-4 inhibitor improves metabolic abnormalities in diabetic mice

OBJECTIVES: Dipeptidyl peptidase-4 inhibition and gastric inhibitory polypeptide (GIP) receptor antagonism have therapeutic effects in type 2 diabetes mellitus. We assessed the effects of sitagliptin and Pro(3)(GIP) in a mouse model of diabetes. METHODS: Diabetes was induced in C57BL/6J mice by a hi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Fei, Dang, Shan, LV, Hongjun, Shi, Bingyin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Pre-Clinical Research Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871083/
https://www.ncbi.nlm.nih.gov/pubmed/33512261
http://dx.doi.org/10.1177/0300060520985664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7871083/
https://www.ncbi.nlm.nih.gov/pubmed/33512261
http://dx.doi.org/10.1177/0300060520985664

Ejemplares similares